In PD-L1-positive patients, the subgroup analysis of the KEYNOTE-590 (3) study showed that ESCC patients with PD-L1 CPS≥10 benefited more than those with CPS<10. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.